 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- LABP-66 / Landos Biopharma
The Novel NLRX1 Activator LABP-66 Attenuates Glial Activation and Limits Neurodegeneration in Late Stage Experimental Encephalomyelitis (Pacific Ballroom) - Feb 7, 2023 - Abstract #ACTRIMSForum2023ACTRIMS_Forum_302;
Abstract is embargoed at this time.